

Included In The 2021 Surviving Sepsis Guidelines¹

NDC

- NDC 68547-501-02: A carton of one 1 mL single-dose vial containing 2.5 mg angiotensin II (as a sterile liquid)
- NDC 68547-005-01: A carton of one 1 mL single-dose vial containing 0.5 mg angiotensin II (as a sterile liquid)

ORDERING

- | | |
|---|---|
| • ASD Healthcare is now AmerisourceBergen specialty distribution | 1-800-746-6273 |
| • Cardinal Health Specialty Pharmaceutical Distribution | 1-866-677-4844 |
| • McKesson Plasma and Biologics | 1-877-625-2566 |
| • Morris & Dickson Co, LLC | 1-800-388-3833 |

HOW SUPPLIED

- GIAPREZA® (angiotensin II) Injection is a clear, aqueous solution for administration by intravenous infusion supplied as a single-dose vial
- Available in 0.5 mg/vial and 2.5 mg/vial options

STORAGE

- GIAPREZA vials should be stored in the refrigerator between 2°C to 8°C (36°F to 46°F)
- Diluted solution may be stored at room temperature or under refrigeration for up to 24 hours, after which it should be discarded

SELECTED IMPORTANT SAFETY INFORMATION

Indication

GIAPREZA® (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Contraindications

None.

Warnings and Precautions

The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in the randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.

Please see additional Important Safety Information throughout. Before administering, please see the [Full Prescribing Information](#) for GIAPREZA.



Learn more at GIAPREZA.com

PREPARATION

- GIAPREZA should be visually inspected for particulate matter and discoloration prior to administration
- Dilute the appropriate amount of GIAPREZA in a normal saline (0.9% sodium chloride) infusion bag to achieve the desired final concentration of 5,000 ng/mL or 10,000 ng/mL
- Discard vial and any unused portion of the drug product after use

Remember that GIAPREZA dosage is measured in nanograms (ng), not micrograms (mcg)

SELECTED IMPORTANT SAFETY INFORMATION (CONT'D)

Adverse Reactions

The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in $\geq 4\%$ of patients treated with GIAPREZA and $\geq 1.5\%$ more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:

La Jolla Pharmaceutical Company
[1-800-651-3861](tel:1-800-651-3861)
medicalinformation@ljpc.com

U.S. Food and Drug Administration
[1-800-FDA-1088](tel:1-800-FDA-1088)
www.fda.gov/medwatch

Please see additional Important Safety Information throughout. Before administering, please see the Full Prescribing Information for GIAPREZA.

Reference: 1. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Crit Care Med.* 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337



INN OVIVA Specialty
Therapeutics

GIAPREZA® is marketed by Innoviva Specialty Therapeutics, Inc. in partnership with La Jolla Pharmaceutical Company.

©2024 Innoviva Specialty Therapeutics™. All rights reserved.

PM-GIA-00081-US | 04/24